Growth, immune and viral responses in HIV infected African children receiving highly active antiretroviral therapy: a prospective cohort study.
about
Predictors of treatment failure and time to detection and switching in HIV-infected Ethiopian children receiving first line anti-retroviral therapyOptimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years oldFactors Associated with the Development of Drug Resistance Mutations in HIV-1 Infected Children Failing Protease Inhibitor-Based Antiretroviral Therapy in South AfricaMagnitude of cytopenias among HIV-infected children in Bahir Dar, northwest Ethiopia: a comparison of HAART-naïve and HAART-experienced childrenAntiretroviral treatment in HIV-infected infants and young children: novel issues raised by the Mississippi babyAetiology and management of malnutrition in HIV-positive children.Challenges in infant and young child nutrition in the context of HIVWeight as predictors of clinical progression and treatment failure: results from the TREAT Asia Pediatric HIV Observational DatabasePoor clinical outcomes for HIV infected children on antiretroviral therapy in rural Mozambique: need for program quality improvement and community engagementPredictors of mortality among children on Antiretroviral Therapy at a referral hospital, Northwest Ethiopia: a retrospective follow up study.Safety and effectiveness of combination antiretroviral therapy during the first year of treatment in HIV-1 infected Rwandan children: a prospective studyAnaemia in HIV-infected children: severity, types and effect on response to HAART.Factors associated with antiretroviral treatment interruption in human immunodeficiency virus (HIV)-1-infected children attending the Jos University Teaching Hospital, Jos, Nigeria.Prevalence and risk factors of undernutrition among antiretroviral-therapy-naïve subjects aged under 5 years old in Makurdi, Nigeria: a retrospective study.Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz.Severe malnutrition and metabolic complications of HIV-infected children in the antiretroviral era: clinical care and management in resource-limited settings.Effect of Age at Antiretroviral Therapy Initiation on Catch-up Growth Within the First 24 Months Among HIV-infected Children in the IeDEA West African Pediatric Cohort.[Impact of antiretroviral therapy on the biological profile of HIV positive children followed-up at Yaounde University Hospital in Cameroon].Growth reconstitution following antiretroviral therapy and nutritional supplementation: systematic review and meta-analysis.CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States.The long-term effectiveness of generic adult fixed-dose combination antiretroviral therapy for HIV-infected Ugandan children.Immunological Response of Hiv-Infected Children to Highly Active Antiretoviral Therapy at Gondar University Hospital, North-Western EthiopiaUnresolved antiretroviral treatment management issues in HIV-infected childrenInitiation of antiretroviral therapy before 6 months of age is associated with faster growth recovery in South African children perinatally infected with human immunodeficiency virusIncidence and risk factors for first line anti retroviral treatment failure among Ugandan children attending an urban HIV clinic.Cohort profile: improving treatment of HIV-infected Ethiopian children through better detection of treatment failure in southern Ethiopia.Factors Determining Survival and Retention among HIV-Infected Children and Adolescents in a Community Home-Based Care and a Facility-Based Family-Centred Approach in Kampala, Uganda: A Cohort Study.Growth failure and nutrition considerations in chronic childhood wasting diseases.Hematologic abnormalities and associated factors among HIV infected children pre- and post-antiretroviral treatment, North West Ethiopia.Universal antiretroviral therapy for HIV-infected children: a review of the benefits and risks to consider during implementation.Growth Recovery Among HIV-infected Children Randomized to Lopinavir/Ritonavir or NNRTI-based Antiretroviral Therapy.Adherence to tablet and liquid formulations of antiretroviral medication for paediatric HIV treatment at an urban clinic in Uganda.Growth in HIV-infected children on long-term antiretroviral therapy.Quantification of CD4 responses to combined antiretroviral therapy over 5 years among HIV-infected children in Kinshasa, Democratic Republic of CongoHigh Levels of Dual-Class Drug Resistance in HIV-Infected Children Failing First-Line Antiretroviral Therapy in Southern Ethiopia.HIV viral suppression and longevity among a cohort of children initiating antiretroviral therapy in Eastern Cape, South Africa
P2860
Q21261820-54979456-7E01-4D76-9828-46F3B5406C47Q24197527-B188053B-9C17-4333-B028-DFF115673AE0Q28546698-249CFDCF-7323-4889-8238-9765E8F1827BQ33439843-379ABA06-1AFB-42C0-9391-74FA9DBE5B7EQ33557037-753A0D6C-712F-4BF8-ACF0-74F0ABFFDFF9Q33659087-FE3960C9-4895-4C14-9DC4-3036AA297408Q34006870-344A53F5-8CBC-46A8-87B0-58F9E3AF8655Q34051420-F18BD7AD-7D92-484C-A1FC-753F360E4627Q34374033-AFBE2E84-30F2-45DA-B63B-EF2AC1DA49F8Q34435987-954B3054-BD59-41FD-9297-594EE3E87E96Q34445856-2696CF62-206C-4172-AF1B-53B7F7197062Q34462882-46162EA6-3FB2-4F9D-9534-8F09038BF8B0Q35041658-1B2F1C4B-2377-4DB5-8465-143C6E89E238Q35284462-495712E8-A443-42A3-9990-6B4F0CD9BF96Q35547048-7AB23F6A-8E46-43BD-8E36-79AB8C6243A3Q35578704-8A05ECFC-D202-4507-A7B8-90B2AB950C57Q35738443-CBE40FC0-3201-4C6F-88EA-5A2F89420221Q35748231-F6EDA390-692C-4EAE-977F-AD3EFF5CB518Q36084809-1E33542A-370F-4C70-A989-D7F2B79D6569Q36180809-582A48FF-4157-4D09-93DC-AD03D28D7281Q36569791-243964EF-80F1-494D-A8FA-766EAC672278Q36605248-4671BAE5-8DAC-4263-95D7-FAFDDE0B75CEQ36781481-EA553BA9-ED5C-4676-B9C8-A6BDB8DD36ACQ36807963-E2C335CB-9299-4F3D-9544-318A9E71B775Q37322060-A932CC5E-31C1-47B2-B13D-F28AEBA04976Q37681409-8ECCAADD-076E-445F-B832-07E5CF3A061CQ37730863-08836F0A-5CF7-4C30-974A-5C8CCB86C53FQ38265982-D890F289-88DF-4B4E-A53F-5E8E1BBCD68DQ38613220-EB4F2F54-55CA-4911-9E22-752615DCFF1CQ38660444-5F037019-FBC2-426C-838E-2BD7412AEB57Q38853193-35F7B734-F5AA-4EFC-97DA-4787728347A3Q38869702-891E951A-41C6-4A07-92D2-51813BA15FFDQ40355257-5506A256-BF8D-4322-B30C-9458AC31621AQ41381835-650CF4B4-E971-4056-B61B-158124127754Q47547186-B604F58F-FF98-43CA-867E-41C5BBAE8FE6Q56938270-18BA5E6F-96AC-487C-B603-240BD965F42F
P2860
Growth, immune and viral responses in HIV infected African children receiving highly active antiretroviral therapy: a prospective cohort study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Growth, immune and viral respo ...... y: a prospective cohort study.
@ast
Growth, immune and viral respo ...... y: a prospective cohort study.
@en
type
label
Growth, immune and viral respo ...... y: a prospective cohort study.
@ast
Growth, immune and viral respo ...... y: a prospective cohort study.
@en
prefLabel
Growth, immune and viral respo ...... y: a prospective cohort study.
@ast
Growth, immune and viral respo ...... y: a prospective cohort study.
@en
P2093
P2860
P356
P1433
P1476
Growth, immune and viral respo ...... y: a prospective cohort study.
@en
P2093
Danstan Bagenda
Linda N Barlow-Mosha
Mary G Fowler
Michael M Mubiru
Patrick Ajuna
Peter Mudiope
Philippa M Musoke
Thorkild Tylleskar
P2860
P2888
P356
10.1186/1471-2431-10-56
P577
2010-08-06T00:00:00Z
P5875
P6179
1007934415